Targeted Antibiotic Prophylaxis and Cotrimoxazole in Transrectal Prostate Biopsy

Overview

This retrospective study of 697 men undergoing transrectal prostate biopsy (TRPB) demonstrated that empiric peri-interventional antibiotic prophylaxis (PAP) with cotrimoxazole is feasible and effective in preventing infectious complications when rectal swabs and urine cultures are inconspicuous. Infectious complication rates were low, and targeted antibiotic adjustments based on microbiological findings were successfully implemented.

Background

Transrectal prostate biopsy is a common diagnostic procedure for suspected prostate cancer but carries a higher risk of infectious complications compared to perineal biopsy. Due to concerns about fluoroquinolone restrictions and antibiotic resistance, alternative prophylactic regimens are needed. Current guidelines recommend rectal swabs and urine cultures to detect resistant bacteria and guide targeted antibiotic prophylaxis. Cotrimoxazole, with broad-spectrum activity against gram-positive and gram-negative bacteria, represents a potential empiric prophylactic agent for TRPB.

Data Highlights

Key Findings

• Empiric PAP with cotrimoxazole was administered in 86% of patients without detected multiresistant bacteria or urinary tract infection.
• Targeted antibiotic prophylaxis was used in patients with positive rectal swabs or urine cultures, including meropenem or piperacillin + tazobactam.
• Multiresistant gram-negative bacteria were detected in 3% of rectal swabs, guiding antibiotic adjustments.
• Common urinary pathogens included Enterococcus species and Escherichia coli.
• Infectious complications were monitored for 21 days post-biopsy, defined by fever, dysuria, or severe prostate pain.
• Logistic regression analyses were performed to identify factors associated with infectious complications.

Clinical Implications

Empiric cotrimoxazole prophylaxis is a viable option for TRPB patients with negative rectal swabs and urine cultures, potentially reducing reliance on broad-spectrum antibiotics and fluoroquinolones. Pre-biopsy microbiological screening remains essential to identify patients requiring targeted antibiotic regimens, thereby minimizing infectious complications and antibiotic resistance risks.

Conclusion

This single-center retrospective analysis supports the feasibility and effectiveness of cotrimoxazole as empiric antibiotic prophylaxis in TRPB when microbiological screening is unremarkable. Tailored antibiotic strategies based on rectal and urine cultures optimize patient safety and antibiotic stewardship.

References

1. European Urology Association Guidelines 2023 -- Prostate Biopsy Recommendations
2. German Federal Institute for Drugs and Medical Devices 2022 -- Fluoroquinolone Restrictions
3. Technical University of Munich Ethics Committee 2022-2023 -- Study Approval
4. Local Microbiological Resistance Patterns Analysis 2023 -- Cotrimoxazole Use in TRPB